Small Cell Lung Cancer: A New Era Is Beginning?
Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positi...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2021 |
Language: | English |
Physical Description: | 1 electronic resource (150 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545168204498 |
---|---|
ctrlnum |
(CKB)5400000000042093 (oapen)https://directory.doabooks.org/handle/20.500.12854/76940 (EXLCZ)995400000000042093 |
collection |
bib_alma |
record_format |
marc |
spelling |
Morabito, Alessandro edt Small Cell Lung Cancer: A New Era Is Beginning? Small Cell Lung Cancer Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 1 electronic resource (150 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positive results in terms of improvement of overall survival obtained with a combination of checkpoint inhibitors (atezolizumab or durvalumab) with platinum-etoposide in patients with extensive disease. Moreover, nivolumab and pembrolizumab showed antitumor activity and received U.S. FDA approval as single agents in patients pretreated with platinum-based therapy and at least one other therapy. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly (ADP-ribose) polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody–drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of extensive SCLC, focusing on the biology of SCLC, immune-checkpoint inhibitors, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques. English Medicine bicssc immune checkpoint inhibitors extensive-stage small cell lung cancer nivolumab ipilimumab pembrolizumab atezolizumab durvalumab chemotherapy small-cell lung cancer lobectomy pneumonectomy radiotherapy multimodal treatment immunotherapy SCLC PARP DDR ICB synthetic lethality SLFN11 STING pathology and classification of SCLC biology of SCLC immune-checkpoint inhibitors in SCLC small cell lung cancer Immunotherapy extensive disease lurbinectedin gene pathway pathobiology targeted therapy circulating tumor cells prognostic biomarker targeted agents 3-0365-2301-4 3-0365-2302-2 Rolfo, Christian edt Morabito, Alessandro oth Rolfo, Christian oth |
language |
English |
format |
eBook |
author2 |
Rolfo, Christian Morabito, Alessandro Rolfo, Christian |
author_facet |
Rolfo, Christian Morabito, Alessandro Rolfo, Christian |
author2_variant |
a m am c r cr |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Small Cell Lung Cancer: A New Era Is Beginning? |
spellingShingle |
Small Cell Lung Cancer: A New Era Is Beginning? |
title_full |
Small Cell Lung Cancer: A New Era Is Beginning? |
title_fullStr |
Small Cell Lung Cancer: A New Era Is Beginning? |
title_full_unstemmed |
Small Cell Lung Cancer: A New Era Is Beginning? |
title_auth |
Small Cell Lung Cancer: A New Era Is Beginning? |
title_alt |
Small Cell Lung Cancer |
title_new |
Small Cell Lung Cancer: A New Era Is Beginning? |
title_sort |
small cell lung cancer: a new era is beginning? |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2021 |
physical |
1 electronic resource (150 p.) |
isbn |
3-0365-2301-4 3-0365-2302-2 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT morabitoalessandro smallcelllungcanceraneweraisbeginning AT rolfochristian smallcelllungcanceraneweraisbeginning AT morabitoalessandro smallcelllungcancer AT rolfochristian smallcelllungcancer |
status_str |
n |
ids_txt_mv |
(CKB)5400000000042093 (oapen)https://directory.doabooks.org/handle/20.500.12854/76940 (EXLCZ)995400000000042093 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Small Cell Lung Cancer: A New Era Is Beginning? |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1787548850550996993 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03555nam-a2200733z--4500</leader><controlfield tag="001">993545168204498</controlfield><controlfield tag="005">20231214132940.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202201s2021 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000042093</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/76940</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000042093</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Morabito, Alessandro</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Small Cell Lung Cancer: A New Era Is Beginning?</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Small Cell Lung Cancer</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (150 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positive results in terms of improvement of overall survival obtained with a combination of checkpoint inhibitors (atezolizumab or durvalumab) with platinum-etoposide in patients with extensive disease. Moreover, nivolumab and pembrolizumab showed antitumor activity and received U.S. FDA approval as single agents in patients pretreated with platinum-based therapy and at least one other therapy. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly (ADP-ribose) polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody–drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of extensive SCLC, focusing on the biology of SCLC, immune-checkpoint inhibitors, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">extensive-stage small cell lung cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nivolumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ipilimumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pembrolizumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">atezolizumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">durvalumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">small-cell lung cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lobectomy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pneumonectomy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radiotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multimodal treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SCLC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PARP</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DDR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ICB</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">synthetic lethality</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SLFN11</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">STING</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pathology and classification of SCLC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biology of SCLC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune-checkpoint inhibitors in SCLC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">small cell lung cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">extensive disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lurbinectedin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene pathway</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pathobiology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">circulating tumor cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognostic biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted agents</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2301-4</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2302-2</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rolfo, Christian</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morabito, Alessandro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rolfo, Christian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:37:27 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337873010004498&Force_direct=true</subfield><subfield code="Z">5337873010004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337873010004498</subfield></datafield></record></collection> |